[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Tobetto et al., 1992 - Google Patents

Inhibitory effects of hyaluronan on [14C] arachidonic acid release from labeled human synovial fibroblasts

Tobetto et al., 1992

View PDF
Document ID
9200828673878367834
Author
Tobetto K
Yasui T
Ando T
Hayaishi M
Motohashi N
Shinogi M
Mori I
Publication year
Publication venue
The Japanese Journal of Pharmacology

External Links

Snippet

The effects of hyaluronan (HA) on the release of arachidonic acid (AA) from phospho lipids induced by bradykinin in synovial fibroblasts of osteoarthritic patients were examined. HA inhib ited [14C] AA release from prelabeled synovial cells stimulated with and without …
Continue reading at www.jstage.jst.go.jp (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Tobetto et al. Inhibitory effects of hyaluronan on [14C] arachidonic acid release from labeled human synovial fibroblasts
Goldstein et al. Inhibition of proteolytic degradation of low density lipoprotein in human fibroblasts by chloroquine, concanavalin A, and Triton WR 1339.
Saxena et al. Transport of lipoprotein lipase across endothelial cells.
Kovanen et al. Regulation of low density lipoprotein receptors by adrenocorticotropin in the adrenal gland of mice and rats in vivo.
Cameron et al. Ascorbic acid and the glycosaminoglycans: an orthomolecular approach to cancer and other diseases
Williams et al. In vitro effects of serum proteins and lipids on lipid synthesis in human skin fibroblasts and leukocytes grown in culture
Schmid et al. Bioenergetics of human peripheral blood mononuclear cell metabolism in quiescent, activated, and glucocorticoid-treated states
Li et al. Mannose‐mediated inhibitory effects of PA‐MSHA on invasion and metastasis of hepatocellular carcinoma via EGFR/Akt/IκBβ/NF‐κB pathway
WO1996016973A1 (en) Keratan sulfate oligosaccharide fraction and drug containing the same
Moseley et al. Augmentation of fibroblast proliferation by bleomycin.
Xian et al. Imperatorin alleviates ROS-mediated airway remodeling by targeting the Nrf2/HO-1 signaling pathway
Alloatti et al. Effect of platelet-activating factor (PAF) on human cardiac muscle
US20230277580A1 (en) Cell protective methods and compositions
Witters et al. An autocrine factor from Reuber hepatoma cells that stimulates DNA synthesis and acetyl-CoA carboxylase. Characterization of biologic activity and evidence for a glycan structure.
Thellman et al. In vitro uptake of [3H] α-tocopherol from low density lipoprotein by cultured human fibroblasts
Rothenberg et al. Biochemical and morphological characterization of basophilic leukocytes from two patients with myelogenous leukemia.
Ma et al. Resveratrol modulates the inflammatory response in hPDLSCs via the NRF2/HO‐1 and NF‐κB pathways and promotes osteogenic differentiation
Raymond et al. Lipoproteins of the extravascular space: enhanced macrophage degradation of low density lipoproteins from interstitial inflammatory fluid
Bankey et al. Tumor necrosis factor production by Kupffer cells requires protein kinase C activation
JP2007291133A (en) Therapeutic agent containing hyaluronic acid oligosaccharide as active ingredient
JPS58172317A (en) 26-hydroxycholesterol medicine for unstriated muscle cell proliferation inhibition and cerebrotendinous xanthomatosis detection
Marzetta et al. Conversion of plasma VLDL and IDL precursors into various LDL subpopulations using density gradient ultracentrifugation.
SCHENGRUND et al. Exogenous Gangliosides: How Do They Cross the Blood‐Brain Barrier and How Do They Inhibit Cell Proliferation? a
Kweifio‐Okai et al. Antiarthritic mechanisms of lupeol triterpenes
Haeffner et al. Cholesterol-induced growth stimulation, cell aggregation, and membrane properties of ascites tumor cells in culture